

What is claimed is:

1. A pharmaceutical composition comprising:
 - (i) a botulinum toxin;
 - (ii) poloxamer 188; and
 - (iii) methionine or N-Acetyl-cysteine.
2. The composition according to claim 1, further comprising trehalose or sucrose, and optionally NaCl, and optionally EDTA.
3. The composition according to claim 2, wherein the relative weight amounts (% w/w) of trehalose or sucrose, poloxamer 188, methionine, and optionally NaCl, and optionally EDTA are within the following ranges:

trehalose or sucrose	1 to 10
poloxamer 188	0.5 to 5
methionine	0.1 to 0.3 and optionally
NaCl	0.1 to 10 and optionally
EDTA	0.01 to 0.1.
4. The composition according to claim 3, wherein the relative weight amounts (% w/w) of trehalose, poloxamer 188, methionine, and optionally NaCl, and optionally EDTA are:
 - a)

trehalose or sucrose	7 to 9
poloxamer 188	3.5 to 4.5
methionine	0.15 to 0.25;

 and are preferably

trehalose or sucrose	8
poloxamer 188	4
methionine	0.2; or
 - b)

trehalose or sucrose	7 to 9
poloxamer 188	0.5 to 0.7
methionine	0.15 to 0.25;

 and are preferably

trehalose or sucrose	8
poloxamer 188	0.6
methionine	0.2; or
 - c)

trehalose or sucrose	1 to 3
poloxamer 188	3.5 to 4.5
methionine	0.15 to 0.25
NaCl	0.4 to 0.8;

and are preferably	trehalose or sucrose	2
	poloxamer 188	4
	methionine	0.2
	NaCl	0.6; or
d)	trehalose or sucrose	7 to 9
	poloxamer 188	3.5 to 4.5
	methionine	0.15 to 0.25
	EDTA	0.01 to 0.05;
and are preferably	trehalose or sucrose	8
	poloxamer 188	4
	methionine	0.2
	EDTA	0.03.

5. The composition according to claim 2, wherein the relative weight amounts (% w/w) of trehalose or sucrose, poloxamer 188, N-Acetyl-cysteine and EDTA are within the following ranges:

trehalose or sucrose	1 to 10
poloxamer 188	0.5 to 5
N-Acetyl-cysteine	0.01 to 0.5, and
EDTA	0.01 to 0.1.

6. The composition according to claim 5, wherein the relative weight amounts (% w/w) of trehalose, poloxamer 188, N-Acetyl-cysteine, and EDTA are:

trehalose or sucrose	7 to 9
poloxamer 188	3.5 to 4.5
N-Acetyl-cysteine	0.1 to 0.3 and
EDTA	0.01 to 0.05;
and are preferably	
trehalose or sucrose	8
poloxamer 188	4
N-Acetyl-cysteine	0.2 and
EDTA	0.03.

7. The composition according to any previous claim, comprising trehalose.

8. A pharmaceutical composition according to claim 1, wherein the composition does not comprise a sugar or polyalcohol.

9. The composition according to claim 8, wherein the relative weight amounts (% w/w) of poloxamer 188, and methionine are within the following ranges:

poloxamer 188	0.5 to 5
methionine	0.1 to 0.3.

10. The composition according to claim 9, wherein the relative weight amounts (% w/w) of poloxamer 188, and methionine are:

poloxamer 188	3.5 to 4.5
methionine	0.15 to 0.25;

and are preferably

poloxamer 188	4
methionine	0.2.

11. The composition according to any one of claims 1 - 10, wherein the composition is a liquid composition, wherein the composition preferably comprises a buffer.

12. The composition according to claim 11, wherein the buffer is histidine, wherein the concentration of histidine is preferably 20 mM, wherein the pH is preferably in the range 5-7, and wherein the pH is most preferably in the range 5.5-6.

13. The composition according to any one of claims 1 - 7, wherein the composition is a solid composition, wherein the composition is preferably lyophilised.

14. The composition according to claim 13, further comprising a buffer, wherein the buffer is preferably histidine, wherein the histidine is preferably comprised in a relative weight amount of 0.1 to 0.5 (% w/w), more preferably in a relative weight amount of 0.3-0.4% (w/w).

15. The composition according to any one of claims 1 to 4, wherein the composition is a liquid composition consisting of one or more botulinum toxins, trehalose or sucrose, poloxamer 188, methionine, a buffer, and optionally NaCl, and optionally EDTA.

16. The composition according to any one of claims 1 to 4, wherein the composition is a solid composition consisting of one or more botulinum toxins, trehalose, poloxamer 188, methionine, a buffer, and optionally NaCl, and optionally EDTA.

17. The composition according to any one of claims 1, 2, 5 and 6, wherein the composition is a liquid composition consisting of one or more botulinum toxins, trehalose or sucrose, poloxamer 188, N-Acetyl-cysteine, a buffer, and EDTA.

18. The composition according to any one of claims 1, and 8 to 10, wherein the composition is a liquid composition and consists of one or more botulinum toxins, poloxamer 188, methionine, and a buffer.
19. The composition according to any previous claim, comprising no animal-derived protein.
20. The composition according to any one of claims 1 to 17 and 19, comprising ethylene diamine tetraacetic acid sodium salt (EDTA) or an EDTA analog.
21. The composition according to claim 20, wherein the relative weight amount (% w/w) of EDTA ranges from about 0.01 to 0.10.
22. A liquid pharmaceutical composition, comprising:
- (i) a Clostridial toxin;
 - (ii) a poloxamer;
 - (iii) a chelating agent; and
 - (iv) a sacrificial antioxidant.
23. The liquid pharmaceutical composition according to claim 22, wherein the chelating agent is EDTA, EGTA or DTPA, and the sacrificial antioxidant is ascorbic acid.
24. A liquid pharmaceutical composition, comprising:
- (i) a Clostridial toxin;
 - (ii) a poloxamer;
 - (iii) a chelating agent; and
 - (iv) a chain terminator.
25. The liquid composition according to claim 24, wherein the chelating agent is EDTA and the chain terminator is N-acetyl-cysteine.
26. The liquid composition according to claim 24, wherein the chelating agent is EDTA and the chain terminator is Butylated hydroxytoluene.
27. A liquid pharmaceutical composition, comprising:
- (i) a Clostridial toxin;
 - (ii) a poloxamer; and
 - (iii) methionine.
28. A liquid pharmaceutical composition, comprising:

- (i) a Clostridial toxin;
- (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof;
- (iii) a poloxamer; and
- (iv) methionine.

29. A liquid pharmaceutical composition, comprising:

- (i) a Clostridial toxin;
- (ii) a tonicity agent selected from trehalose, sucrose, sodium chloride, mannitol, sorbitol, glucose, and combinations thereof;
- (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof;
- (iv) a chelating agent; and
- (v) a chain terminator.

30. A lyophilized pharmaceutical composition, comprising:

- (i) a Clostridial toxin;
- (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;
- (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof;
- (iv) a chelating agent; and
- (v) a sacrificial antioxidant.

31. A lyophilized pharmaceutical composition, comprising:

- (i) a Clostridial toxin;
- (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;
- (iii) a poloxamer;
- (iv) a chelating agent; and
- (v) a sacrificial antioxidant.

32. The composition according to any one of claims 30 to 31, wherein the chelating agent is EDTA, EGTA or DTPA, and the sacrificial antioxidant is ascorbic acid.

33. A lyophilized pharmaceutical composition, comprising:

- (i) a Clostridial toxin;
- (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;
- (iii) a poloxamer;
- (iv) a chelating agent; and
- (v) a chain terminator.

34. A lyophilized pharmaceutical composition, comprising:
- (i) a Clostridial toxin;
 - (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;
 - (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof;
 - (iv) a chelating agent; and
 - (v) a chain terminator.
35. The lyophilized pharmaceutical composition according to any one of claims 33-34, wherein the chelating agent is EDTA and the chain terminator is N-Acetyl-cysteine.
36. A lyophilized pharmaceutical composition, comprising:
- (i) a Clostridial toxin;
 - (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;
 - (iii) a poloxamer; and
 - (iv) a chain terminator.
37. A lyophilized pharmaceutical composition, comprising:
- (i) a Clostridial toxin;
 - (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;
 - (iii) a surfactant selected from a poloxamer, a polysorbate and combinations thereof; and
 - (iv) a chain terminator.
38. The lyophilized pharmaceutical composition according to any one of claims 36-37, wherein the chain terminator is N-Acetyl-cysteine.
39. A lyophilized pharmaceutical composition, comprising:
- (i) a Clostridial toxin;
 - (ii) trehalose, sucrose, mannitol, sorbitol, glucose, or combinations thereof;
 - (iii) a poloxamer; and
 - (iv) methionine.
40. A method of treating, reducing the symptoms, and/or prevention of diseases, disorders, and conditions, wherein the method comprises the step of administering the pharmaceutical composition of any preceding claim to a subject in need thereof.
41. The method of claim 40, wherein the diseases, disorders, and conditions are selected from neuromuscular diseases, pain, psychological disorders, urological disorders, inflammation, and skin disorders.

- 42. The method of claim 41, wherein the disorder is depression.
- 43. The method of claim 41, wherein the condition is cardiac arrhythmia.
- 44. A method of cosmetic treatment comprising the step of administering the pharmaceutical composition of any of claims 1 to 39 to a subject in need thereof.